-transparent.png){kind=logo}
The two monoamine oxidase (MAO) inhibitors phenelzine and brofaromine given for 2 to 3 weeks were compared in six volunteers. Blood pressure sensitivity to intravenous tyramine increased 2.6-fold during phenelzine (60 mg/day) and 4.8-fold during brofaromine, whereas sensitivity to oral tyramine increased more during phenelzine (15.7-fold vs 8.5-fold). After withdrawal of phenelzine, pressor sensitivity to oral tyramine returned to control values within 2 and for more than 8 weeks. Relative bioavailability of conjugated tyramine was elevated sixfold by brofaromine and 11.6-fold by phenelzine. Urinary elimination of tryptamine increased during phenelzine and brofaromine to 12.7-fold and threefold, respectively. 3-Methoxy-4-hydroxyphenylglycol (MHPG) and 3-methoxy-4-hydroxymandelic acid (VMA) excretion decreased during brofaromine significantly by 72% and 49%, respectively. The nonsignificant decrease of MHPG excretion and the increase of intravenous tyramine pressor sensitivity caused by phenelzine are significantly related. The data suggest that the selective reversible MAO-A inhibitor brofaromine has a larger therapeutic safety than phenelzine.
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
January 1994,
Journal of neural transmission. General section,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
June 1991,
Biochemical pharmacology,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
March 1993,
Biological psychiatry,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
April 1993,
Biopharmaceutics & drug disposition,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
January 1982,
European journal of clinical pharmacology,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
December 1989,
Neuroscience letters,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
April 1978,
The American journal of psychiatry,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
February 1989,
British journal of clinical pharmacology,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
January 1993,
Clinical neuropharmacology,
P R Bieck, and
L Firkusny, and
C Schick, and
K H Antonin, and
E Nilsson, and
R Schulz, and
M Schwenk, and
H Wollmann
November 1979,
Psychological medicine,
